Guidelines developed by expert panels commissioned by the International AIDS Society – USA are published in the Journal of the American Medical Association (JAMA)

New IAS guidelines recommend Invirase/r for initial antiretroviral therapy  

Invirase boosted with low dose ritonavir is one of the recommended protease inhibitor components of initial antiretroviral regimens in the revised International AIDS Society-USA guidelines for the treatment of adult HIV infection. The guidelines were published in the July 14^th issue of the Journal of the American Medical Association (JAMA). Boosted Invirase received a 1A rating, which is the highest position in the guidelines based on strength of clinical evidence.

“Treatment for Adult HIV Infection 2004 Recommendations of the International AIDS Society-USA Panel”, JAMA, 292: 251-265

IAS guidelines confirms FUZEON’s role

In July during the XV International AIDS Conference in Bangkok, the International AIDS Society (IAS) unveiled their 2004 recommendations for the treatment for adult HIV infection in a special issue of the Journal of the American Medical Association¹. Now that there are four classes, the new drug section includes clear recommendations, based on its excellent efficacy and safety profile, on when to use FUZEON, the first fusion inhibitor and the most recent breakthrough in HIV treatment.

The IAS authors conclude that FUZEON ‘is best considered at the time of the second, third or fourth failure, depending on the number of active drugs that remain as options.’ They add that if FUZEON is used too late, the outcome may be compromised, as there might not be enough active drugs to combine it with.

The IAS guidelines corroborate the FUZEON specific consensus guidelines published in AIDS², in May 2004. The consensus guidelines that provided in-depth advice on when and how to use FUZEON focussed on providing a framework to meet the challenges raised by the fact that FUZEON is the first injectable anti-retroviral, concluding that with ongoing training and support, healthcare professionals can assist patients in successfully introducing FUZEON into their daily routines.

1 P. Yeni et al. Recommendations for Adult HIV infection. JAMA, July 14, 2004-Vol 292, No2: 251-265

2 Clotet B, Raffi R, Cooper D, et al. Clinical management of pre-treated, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004; 18: 1137-1146

	Recommendations for the Use of HIV Resistance Testing (Hirsch MS, et al. CID. 2003)
	Recommendations for the Use of Antiretroviral Therapy (Yeni et al., JAMA 2004)
	Please click on the icons to view any of the guidelines listed above.

These guidelines are available online at http://www.iasusa.org/pub/index.html